Terrence F Blaschke

List of Publications by Year
in descending order

156	14,091	57631	20307
papers	citations	44 h-index	116 g-index

156	156	156	14614
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Adherence to Medication. New England Journal of Medicine, 2005, 353, 487-497.	13.9	6,773
2	Asymmetric Dimethylarginine (ADMA): A Novel Risk Factor for Endothelial Dysfunction. Circulation, 1998, 98, 1842-1847.	1.6	1,088
3	SEXDIFFERENCES INPHARMACOKINETICS ANDPHARMACODYNAMICS. Annual Review of Pharmacology and Toxicology, 2004, 44, 499-523.	4.2	438
4	Adherence to Medications: Insights Arising from Studies on the Unreliable Link Between Prescribed and Actual Drug Dosing Histories. Annual Review of Pharmacology and Toxicology, 2012, 52, 275-301.	4.2	332
5	Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047. Aids, 2002, 16, 569-577.	1.0	293
6	Protein Binding and Kinetics of Drugs in Liver Diseases. Clinical Pharmacokinetics, 1977, 2, 32-44.	1.6	269
7	Disposition of ketoconazole, an oral antifungal, in humans. Antimicrobial Agents and Chemotherapy, 1982, 21, 151-158.	1.4	217
8	Protein Binding in Antiretroviral Therapies. AIDS Research and Human Retroviruses, 2003, 19, 825-835.	0.5	173
9	Enhanced Bioavailability and Decreased Clearance of Analgesics in Patients with Cirrhosis. Gastroenterology, 1979, 77, 96-102.	0.6	137
10	Improving antiretroviral therapy adherence in resourceâ€limited settings at scale: a discussion of interventions and recommendations. Journal of the International AIDS Society, 2017, 20, 21371.	1.2	134
11	Asymmetric Dimethylarginine Increases Mononuclear Cell Adhesiveness in Hypercholesterolemic Humans. Arteriosclerosis, Thrombosis, and Vascular Biology, 2000, 20, 1040-1046.	1.1	123
12	Interaction of Anti-HIV Protease Inhibitors With the Multidrug Transporter P-Glycoprotein (P-gp) in Human Cultured Cells. Journal of Acquired Immune Deficiency Syndromes, 1998, 19, 203-209.	0.3	122
13	Characterizing patterns of drug-taking behavior with a multiple drug regimen in an AIDS clinical trial. Aids, 1998, 12, 2295-2303.	1.0	113
14	Pharmacokinetics of intravenous and oral Lâ€arginine in normal volunteers. British Journal of Clinical Pharmacology, 1999, 47, 261-266.	1.1	94
15	Pharmacokinetics of rifabutin. Antimicrobial Agents and Chemotherapy, 1989, 33, 1237-1241.	1.4	91
16	Nicotine impairs endothelium-dependent dilatation in human veins in vivo. Clinical Pharmacology and Therapeutics, 2000, 67, 391-397.	2.3	89
17	Crigler-Najjar Syndrome: An Unusual Course with Development of Neurologic Damage at Age Eighteen. Pediatric Research, 1974, 8, 573-590.	1.1	87
18	Optimizing the science of drug development: opportunities for better candidate selection and accelerated evaluation in humans. Pharmaceutical Research, 2000, 17, 1335-1344.	1.7	87

#	Article	IF	Citations
19	Gentamicin pharmacokinetics in neonates undergoing extracorporal membrane oxygenation. Pediatric Infectious Disease Journal, 1990, 9, 562-565.	1.1	79
20	Optimizing the Science of Drug Development: Opportunities for Better Candidate Selection and Accelerated Evaluation in Humans. Journal of Clinical Pharmacology, 2000, 40, 803-814.	1.0	77
21	A Markov mixed effect regression model for drug compliance. , 1998, 17, 2313-2333.		74
22	Nifedipine pharmacokinetics during preterm labor tocolysis. American Journal of Obstetrics and Gynecology, 1989, 161, 1485-1490.	0.7	72
23	Amitriptyline disposition in young and elderly normal men. Clinical Pharmacology and Therapeutics, 1983, 33, 360-366.	2.3	68
24	In vivo interaction of the enantiomers of disopyramide in human subjects. Journal of Pharmacokinetics and Pharmacodynamics, 1986, 14, 335-356.	0.6	64
25	Morphine-induced venodilation in humans*. Clinical Pharmacology and Therapeutics, 1996, 60, 554-560.	2.3	64
26	Clinical Pharmacokinetics of Rifabutin. Clinical Pharmacokinetics, 1995, 28, 115-125.	1.6	63
27	Influence of acute viral hepatitis on phenytoin kinetics and protein binding. Clinical Pharmacology and Therapeutics, 1975, 17, 685-691.	2.3	62
28	NALOXONE LOWERS PLASMA-PROLACTIN IN MAN. Lancet, The, 1979, 313, 1293.	6.3	62
29	Influence of viral hepatitis on the disposition of two compounds with high hepatic clearance: Lidocaine and indocyanine green. Clinical Pharmacology and Therapeutics, 1976, 20, 290-299.	2.3	61
30	Understanding Forgiveness: Minding and Mining the Gaps Between Pharmacokinetics and Therapeutics. Clinical Pharmacology and Therapeutics, 2010, 88, 457-459.	2.3	61
31	Influence of acute viral hepatitis on disposition and plasma binding of tolbutamide. Clinical Pharmacology and Therapeutics, 1977, 21, 301-309.	2.3	59
32	Effect of naloxone, a specific opioid inhibitor, on blood pressure fall during sleep.. Circulation, 1981, 63, 117-121.	1.6	59
33	Discrepancies Between Pharmacokinetic Studies of Amitriptyline. Clinical Pharmacokinetics, 1985, 10, 257-268.	1.6	59
34	Poor medication adherence in clinical trials: consequences and solutions. Nature Reviews Drug Discovery, 2017, 16, 149-150.	21.5	58
35	Venodilation in Raynaud's disease. Lancet, The, 1993, 342, 1451-1454.	6.3	57
36	Do we need full compliance data for population pharmacokinetic analysis?. Journal of Pharmacokinetics and Pharmacodynamics, 1996, 24, 265-282.	0.6	57

#	Article	IF	Citations
37	High-Performance Liquid Chromatographic Assay for the Quantitation ofl-Arginine in Human Plasma. Analytical Chemistry, 1996, 68, 3520-3523.	3.2	56
38	Usability of a Medication Event Reminder Monitor System (MERM) by Providers and Patients to Improve Adherence in the Management of Tuberculosis. International Journal of Environmental Research and Public Health, 2017, 14, 1115.	1.2	56
39	The extent of non-adherence in a large AIDS clinical trial using plasma dideoxynucleoside concentrations as a marker. Aids, 1998, 12, 2305-2311.	1.0	55
40	Hepatic First-pass Metabolism in Liver Disease. Clinical Pharmacokinetics, 1979, 4, 423-432.	1.6	54
41	Response optimization of drug dosage: Antiarrhythmie studies with tocainide. Clinical Pharmacology and Therapeutics, 1977, 22, 42-57.	2.3	53
42	Atenolol determination by high-performance liquid chromatography and fluorescence detection. Journal of Chromatography A, 1979, 171, 357-362.	1.8	52
43	Application of Salivary Concentration Data to Pharmacokinetic Studies with Antipyrine. Journal of Pharmaceutical Sciences, 1977, 66, 135-137.	1.6	48
44	Administration of heparin causes release of non-esterified fatty acids in human plasma. Life Sciences, 1980, 27, 771-780.	2.0	48
45	Furosemide Disposition in Cirrhotic Patients. Gastroenterology, 1981, 81, 1012-1016.	0.6	47
46	Drugs and the liverâ€"I. Biochemical Pharmacology, 1974, 23, 2795-2806.	2.0	46
47	Responsiveness of superficial hand veins to phenylephrine in essential hypertension. Alpha adrenergic blockade during prazosin therapy.. Journal of Clinical Investigation, 1989, 83, 108-112.	3.9	45
48	Absence of age-related changes in venous responsiveness to nitroglycerin in vivo in humans. Clinical Pharmacology and Therapeutics, 1987, 42, 521-524.	2.3	44
49	Wirelessly observed therapy compared to directly observed therapy to confirm and support tuberculosis treatment adherence: A randomized controlled trial. PLoS Medicine, 2019, 16, e1002891.	3.9	44
50	Studies on the clinical pharmacology of prazosin. II: The influence of indomethacin and of propranolol on the action and disposition of prazosin.. British Journal of Clinical Pharmacology, 1980, 10, 33-39.	1.1	42
51	The effect of saturable binding to plasma proteins on the pharmacokinetic properties of disopyramide. Journal of Pharmacokinetics and Pharmacodynamics, 1982, 10, 1-14.	0.6	41
52	Heparin-induced vasodilation in human hand veins*. Clinical Pharmacology and Therapeutics, 1999, 66, 232-238.	2.3	39
53	Ageâ€related changes in adenosine and betaâ€adrenoceptor responsiveness of vascular smooth muscle in man.. British Journal of Clinical Pharmacology, 1992, 33, 83-87.	1.1	38
54	Effect of Induced Fever on Sulfobromophthalein Kinetics in Man. Annals of Internal Medicine, 1973, 78, 221.	2.0	38

#	Article	IF	Citations
55	Influence of acute viral hepatitis on disposition and pharmacologic effect of warfarin. Clinical Pharmacology and Therapeutics, 1976, 20, 90-97.	2.3	37
56	Influence of congestive heart failure on prazosin kinetics. Clinical Pharmacology and Therapeutics, 1979, 25, 790-794.	2.3	37
57	Histamine-induced venodilation in human beings involves both H1 and H2 receptor subtypes. Journal of Allergy and Clinical Immunology, 1994, 93, 606-614.	1.5	37
58	Studies on the clinical pharmacology of prazosin. I: Cardiovascular, catecholamine and endocrine changes following a single dose.. British Journal of Clinical Pharmacology, 1980, 10, 23-32.	1.1	36
59	High-Pressure Liquid Chromatographic Analysis of drugs in Biological Fluids I: Warfarin. Journal of Pharmaceutical Sciences, 1977, 66, 142-144.	1.6	35
60	Mechanism of Bradykinin-Induced Venodilation in Humans. Journal of Cardiovascular Pharmacology, 1993, 21, 241-248.	0.8	35
61	Zidovudine response relationships in early human immunodeficiency virus infection. Clinical Pharmacology and Therapeutics, 1993, 54, 556-566.	2.3	33
62	Collaborative International Research in Clinical and Longitudinal Experience Study in NMOSD. Neurology: Neuroimmunology and NeuroInflammation, 2019, 6, e583.	3.1	33
63	Vascular reactivity to phenylephrine and angiotensin II: Comparison of direct venous and systemic vascular responses. Clinical Pharmacology and Therapeutics, 1992, 51, 68-75.	2.3	31
64	Comparative anticholinergic potencies of R- and S- disopyramide in longitudinal muscle strips from guinea pig ileum. Life Sciences, 1980, 27, 1191-1197.	2.0	30
65	Optimizing the science of drug development: opportunities for better candidate selection and accelerated evaluation in humans. European Journal of Pharmaceutical Sciences, 2000, 10, iv-xiv.	1.9	30
66	Determination of nelfinavir free drug concentrations in plasma by equilibrium dialysis and liquid chromatography/tandem mass spectrometry: important factors for method optimization. European Journal of Pharmaceutical Sciences, 2002, 15, 185-195.	1.9	30
67	Measurement of ketoconazole, a new antifungal agent, by high-performance liquid chromatography. Biomedical Applications, 1982, 227, 510-515.	1.7	29
68	Angiotensin-converting enzyme inhibition improves venous endothelial dysfunction in chronic smokers. Clinical Pharmacology and Therapeutics, 1999, 65, 295-303.	2.3	29
69	Differences between the Plasma Indocyanine Green Disappearance Rates of Normal Men and Women. Experimental Biology and Medicine, 1975, 150, 612-617.	1.1	28
70	Comparison of Age-Related Changes in Prostaglandin E1 and Beta-Adrenergic Responsiveness of Vascular Smooth Muscle in Adult Males. Journal of Gerontology, 1989, 44, M13-M17.	2.0	27
71	Pharmacokinetics of L-arginine during chronic administration to patients with hypercholesterolaemia. Clinical Science, 1999, 96, 199-207.	1.8	27
72	Responsiveness of superficial hand veins to Î±-adrenoceptor agonists in insulin-dependent diabetic patients. Clinical Science, 1992, 82, 163-168.	1.8	26

#	Article	IF	Citations
73	Prazosin protein binding in health and disease.. British Journal of Clinical Pharmacology, 1980, 9, 177-182.	1.1	25
74	The Undereducated Physician's Therapeutic Decisions. New England Journal of Medicine, 1983, 308, 1473-1474.	13.9	24
75	Theophylline toxicity subsequent to ranitidine administration: A possible drug-drug interaction. American Journal of Medicine, 1989, 86, 129-132.	0.6	24
76	Effects of ketoconazole on the polymorphic 4â€hydroxylations of Sâ€•mephenytoin and debrisoquine.. British Journal of Clinical Pharmacology, 1989, 28, 161-165.	1.1	24
77	Introducing medical students to medication noncompliance*. Clinical Pharmacology and Therapeutics, 1996, 59, 577-582.	2.3	24
78	Measurement of furosemide by high-performance liquid chromatography. Journal of Chromatography A, 1979, 174, 469-473.	1.8	23
79	High-Pressure Liquid Chromatographic Determination of Amitriptyline and Its Major Metabolites in Human Whole Blood. Journal of Pharmaceutical Sciences, 1982, 71, 581-583.	1.6	22
80	Pharmacokinetics of high-dose oral CCNU in bone marrow transplant patients. Cancer Chemotherapy and Pharmacology, 1996, 38, 425-430.	1.1	21
81	Toward Consensus on Correct Interpretation of Protein Binding in Plasma and Other Biological Matrices for COVIDâ€19 Therapeutic Development. Clinical Pharmacology and Therapeutics, 2021, 110, 64-68.	2.3	21
82	Plasma catecholamines in man are not influenced by the inhibition of prostaglandin synthesis. Prostaglandins, 1979, 17, 581-585.	1.2	19
83	Absence of effect of heparin on the binding of prazosin and phenytoin to plasma proteins. Biochemical Pharmacology, 1980, 29, 3337-3340.	2.0	19
84	Primum non nocere? Valuing of the risk of drug toxicity in therapeutic decision making. Clinical Pharmacology and Therapeutics, 1993, 53, 285-291.	2.3	19
85	Decreased Responsiveness of Superficial Hand Veins to Phenylephrine in Black Normotensive Males. Journal of Cardiovascular Pharmacology, 1990, 16, 177-181.	0.8	18
86	The Stereoselective Disposition of Disopyramide in the Dog. Journal of Cardiovascular Pharmacology, 1980, 2, 825-832.	0.8	17
87	Comparison of vasodilatory responses to nitroglycerin and its dinitrate metabolites in human veins. Clinical Pharmacology and Therapeutics, 1992, 52, 590-596.	2.3	17
88	High-pressure liquid chromatographic analysis of drugs in biological fluids. Journal of Chromatography A, 1977, 137, 145-152.	1.8	16
89	Gas chromatographic analysis of pentazocine. Journal of Chromatography A, 1978, 154, 256-260.	1.8	16
90	Effect of Concentration-Dependent Binding to Plasma Proteins on the Pharmacokinetics and Pharmacodynamics of Disopyramide. Clinical Pharmacokinetics, 1984, 9, 42-48.	1.6	16

#	Article	IF	Citations
91	A semiparametric method for describing noisy population pharmacokinetic data. Journal of Pharmacokinetics and Pharmacodynamics, 1997, 25, 615-642.	0.6	16
92	Model-based Analysis of the Pharmacokinetic Interactions Between Ritonavir, Nelfinavir, and Saquinavir after Simultaneous and Staggered Oral Administration. Drug Metabolism and Disposition, 2002, 30, 1455-1461.	1.7	16
93	Effect of simultaneous versus staggered dosing on pharmacokinetic interactions of protease inhibitors. Clinical Pharmacology and Therapeutics, 2003, 73, 406-416.	2.3	16
94	Glutathione S-transferase Î¼ polymorphism does not explain variation in nitroglycerin responsiveness. Clinical Pharmacology and Therapeutics, 1993, 53, 463-468.	2.3	15
95	Interaction of clofibrate with warfarin. I. Effect of clofibrate on the disposition of the optical enantiomorphs of warfarin. Journal of Pharmacokinetics and Pharmacodynamics, 1977, 5, 495-505.	0.6	14
96	Effect of Etomidate on Hepatic Drug Metabolism in Humans. Anesthesiology, 1988, 68, 920-924.	1.3	14
97	Characterization of nelfinavir binding to plasma proteins and the lack of drug displacement interactions. HIV Medicine, 2006, 7, 122-128.	1.0	14
98	Calculation of drug concentration in plasma after equilibrium dialysis.. British Journal of Clinical Pharmacology, 1982, 14, 752-754.	1.1	13
99	Effect of temazepam on blood pressure regulation in healthy elderly subjects.. British Journal of Clinical Pharmacology, 1990, 29, 61-67.	1.1	13
100	Introduction to the Theme â€œIon Channels and Neuropharmacology: From the Past to the Futureâ€• Annual Review of Pharmacology and Toxicology, 2020, 60, 1-6.	4.2	13
101	The World Health Organization Prequalification Program and Clinical Pharmacology in 2030. Clinical Pharmacology and Therapeutics, 2020, 107, 68-71.	2.3	13
102	Prazosin First-Pass Metabolism and Hepatic Extraction in the Dog. Journal of Cardiovascular Pharmacology, 1979, 1, 641-648.	0.8	12
103	Desensitization of Î²-Adrenoceptorâ€“ and Prostaglandin E1 Receptorâ€“Mediated Human Vascular Smooth Muscle Relaxation. Journal of Cardiovascular Pharmacology, 1992, 19, 447-452.	0.8	12
104	H1- and H2-histamine receptorâ€”mediated vasodilation varies with aging in humans*. Clinical Pharmacology and Therapeutics, 1995, 58, 73-80.	2.3	12
105	Chloroquine-induced venodilation in human hand veins*. Clinical Pharmacology and Therapeutics, 1997, 61, 677-683.	2.3	12
106	Introduction to the Theme â€œPrecision Medicine and Prediction in Pharmacologyâ€• Annual Review of Pharmacology and Toxicology, 2015, 55, 11-14.	4.2	12
107	Quantitation of Radio-Labelled Vitamin K1 and Vitamin K1 Epoxide in Plasma by High Pressure Liquid Chromatography. Thrombosis and Haemostasis, 1978, 39, 466-473.	1.8	12
108	Effect of low doses of heparin on the plasma binding of phenytoin and prazosin in normal man. European Journal of Clinical Pharmacology, 1983, 25, 211-214.	0.8	11

#	Article	IF	Citations
109	PHARMACODYNAMICS OF CYCLOSPORINE-KETOCONAZOLE INTERACTION IN MICE. Transplantation, 1987, 43, 529-532.	0.5	11
110	Dose-dependent inhibition of cyclosporine metabolism in mice by fluconazole. Canadian Journal of Physiology and Pharmacology, 1990, 68, 89-93.	0.7	11
111	Global Challenges for Clinical Pharmacology in the Developing World. Clinical Pharmacology and Therapeutics, 2009, 85, 579-581.	2.3	11
112	A Systematic Evaluation of Effect of Adherence Patterns on the Sample Size and Power of a Clinical Study. CPT: Pharmacometrics and Systems Pharmacology, 2018, 7, 818-828.	1.3	11
113	Advanced computer programs for drug dosing that combine pharmacokinetic and symbolic modeling of patients. Journal of Biomedical Informatics, 1992, 25, 29-42.	0.7	10
114	Role of nitric oxide in isoprenaline and sodium nitroprussideâ€induced relaxation in human hand veins. British Journal of Clinical Pharmacology, 1999, 47, 91-98.	1.1	10
115	Vitamin K1, vitamin K1 epoxide and warfarin interrelationships in the dog. Biochemical Pharmacology, 1981, 30, 2931-2936.	2.0	9
116	Synthesis and anticholinergic properties of the enantiomers of 4-(isopropylamino)-2-(2-pyridyl)-2-phenylbutyramide, the mono-N-dealkylated metabolite of disopyramide. Journal of Medicinal Chemistry, 1981, 24, 614-617.	2.9	9
117	Improving drug dosing in hospitalized patients: automated modeling of pharmacokinetics for individualization of drug dosage regimens. Computer Methods and Programs in Biomedicine, 1989, 30, 169-176.	2.6	9
118	Responsiveness of Peripheral Veins to Transdermal and Sublingual Nitroglycerin in Healthy Male Volunteers. Journal of Cardiovascular Pharmacology, 1989, 14, 534-541.	0.8	9
119	Incorporating Pharmacokinetic/Pharmacodynamic Modeling in Drug Developmentâ€"Are We Ready?. Drug Information Journal, 1992, 26, 119-124.	0.5	9
120	Increased Vascular Î±1-Adrenergic Sensitivity in Patients With Renal Failure. American Journal of Therapeutics, 2007, 14, 427-434.	0.5	9
121	Introduction to the Theme â€œNew Methods and Novel Therapeutic Approaches in Pharmacology and Toxicologyâ€. Annual Review of Pharmacology and Toxicology, 2017, 57, 13-17.	4.2	9
122	Growth hormone release after acute amitriptyline administration to normal human subjects. Psychopharmacology, 1982, 76, 299-301.	1.5	8
123	Desensitization of Nitrate-Induced Venodilation: Reversal with Oral N-Acetylcysteine in Humans. Journal of Cardiovascular Pharmacology, 1992, 20, 907-912.	0.8	8
124	Integrative Continuum: Accelerating Therapeutic Advances in Rare Autoimmune Diseases. Annual Review of Pharmacology and Toxicology, 2012, 52, 523-547.	4.2	8
125	Scientific considerations for global drug development. Science Translational Medicine, 2020, 12, .	5.8	8
126	Measurement of antipyrine halfâ€life from urinary drug concentrations [letter]. British Journal of Clinical Pharmacology, 1984, 18, 650-652.	1.1	7

#	Article	IF	Citations
127	Stereoselective binding of disopyramide to plasma proteins. Pharmaceutical Research, 1988, 05, 316-318.	1.7	7
128	Inhibition of angiotensin-converting enzyme in human hand veins. Clinical Pharmacology and Therapeutics, 1999, 65, 58-65.	2.3	7
129	Variable adherence to prescribed dosing regimens for protease inhibitors: scope and outcomes. Current Opinion in HIV and AIDS, 2008, 3, 603-607.	1.5	7
130	Effect of phenobarbitone on the disposition of lignocaine and warfarin in the dog*. Journal of Pharmacy and Pharmacology, 2011, 30, 804-805.	1.2	7
131	Responsiveness of superficial hand veins to adrenergic stimuli in patients with cystic fibrosis. Clinical Science, 1989, 76, 283-287.	1.8	6
132	Phenobarbital does not increase early labeling of bilirubin from 4-[14C]-Î´-aminolevulinic acid in man and rat. Hepatology, 1991, 14, 1153-1160.	3.6	6
133	Improving Data Reliability Using a Non-Compliance Detection Method versus Using Pharmacokinetic Criteria. Journal of Pharmacokinetics and Pharmacodynamics, 2007, 34, 35-55.	0.8	6
134	Augmentation of Bilirubin UDP Glucuronyltransferase Activity in Rat Liver Homogenates by Glutethimide. Experimental Biology and Medicine, 1972, 140, 1315-1318.	1.1	5
135	Saliva and plasma levels and plasma protein binding of clofibrinic acid in uremic patients. Clinical Pharmacology and Therapeutics, 1980, 27, 230-235.	2.3	5
136	Venous responsiveness to atrial natriuretic factor in man.. British Journal of Clinical Pharmacology, 1988, 26, 797-799.	1.1	5
137	Probenecid inhibition of methotrexate excretion from cerebrospinal fluid in dogs. Journal of Pharmacokinetics and Pharmacodynamics, 1978, 6, 389-397.	0.6	4
138	Plasma antipyrine halfâ€life can be determined from urine data.. British Journal of Clinical Pharmacology, 1987, 23, 715-719.	1.1	4
139	Responsiveness of peripheral veins to vasodilators and the effect of nifedipine on Î±-adrenergic responsiveness in hypertension. Clinical Pharmacology and Therapeutics, 1991, 50, 192-198.	2.3	4
140	Clinical pharmacology comes of age. Clinical Pharmacology and Therapeutics, 1989, 46, 485-488.	2.3	3
141	Effect of Heparin on the Red Blood Cell-to-Plasma Concentration Ratio of Diphenylhydantoin and Prazosin. Therapeutic Drug Monitoring, 1983, 5, 497-500.	1.0	2
142	Electrophysiology of the Enantiomers of Disopyramide in Dogs. Journal of Cardiovascular Pharmacology, 1985, 7, 884-890.	0.8	2
143	Effect of liver disease on dose optimization. International Congress Series, 2001, 1220, 247-258.	0.2	2
144	Introduction to the Theme â€œNew Approaches for Studying Drug and Toxicant Action: Applications to Drug Discovery and Developmentâ€. Annual Review of Pharmacology and Toxicology, 2018, 58, 33-36.	4.2	2

#	Article	IF	Citations
145	High-performance liquid chromatographic analysis of hypoxanthine arabinoside in plasma. Biomedical Applications, 1984, 307, 410-415.	1.7	1
146	Pharmacokinetics: Absorption, Distribution, Metabolism, Excretion Overview Chapter. , 2012, , 21-26.		1
147	Introduction to the Theme â€œOld and New Toxicology: Interfaces with Pharmacologyâ€• Annual Review of Pharmacology and Toxicology, 2021, 61, 1-7.	4.2	1
148	Introduction to the Theme â€œNew Insights, Strategies, and Therapeutics for Common Diseasesâ€• Annual Review of Pharmacology and Toxicology, 2022, 62, 19-24.	4.2	1
149	Pharmacokinetic Interaction of Single Doses of Quinine and Digoxin in Dogs. Pharmacology, 1984, 28, 343-346.	0.9	0
150	Dexamethasone Decreases Plasma Protein Binding of Prazosin In Vivo in Rabbits. Clinical Pharmacokinetics, 1984, 9, 100-101.	1.6	0
151	Etomidate Inhibits Antipyrine Metabolism in Mice. American Journal of the Medical Sciences, 1987, 293, 361-365.	0.4	0
152	The perils of public health by press release. Lancet, The, 2004, 364, 1037-1038.	6.3	0
153	Introduction to the Theme â€œCancer Pharmacologyâ€• Annual Review of Pharmacology and Toxicology, 2016, 56, 19-22.	4.2	0
154	Introduction to the Theme â€œNew Therapeutic Targetsâ€• Annual Review of Pharmacology and Toxicology, 2019, 59, 15-20.	4.2	0
155	Effects of smoking on vascular reactivity.Evaluation by dorsal hand vein technique.. Japanese Journal of Clinical Pharmacology and Therapeutics, 1995, 26, 119-120.	0.1	0
156	Intra-subject variation and individual difference of Zidovudine phosphorylation in human peripheral blood submerged monocyte.. Japanese Journal of Clinical Pharmacology and Therapeutics, 1996, 27, 33-34.	0.1	0